Farmers & Merchants Investments Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 164,235 shares of the company’s stock after acquiring an additional 1,954 shares during the period. Johnson & Johnson comprises 1.0% of Farmers & Merchants Investments Inc.’s holdings, making the stock its 18th biggest holding. Farmers & Merchants Investments Inc.’s holdings in Johnson & Johnson were worth $27,184,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in JNJ. Moneta Group Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $4,609,399,000. Providence Capital Advisors LLC boosted its stake in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after purchasing an additional 4,747,612 shares in the last quarter. Morgan Stanley boosted its stake in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock valued at $31,231,193,000 after purchasing an additional 2,688,798 shares in the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
JNJ has been the topic of a number of recent analyst reports. HSBC initiated coverage on Johnson & Johnson in a research note on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 18th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Finally, Raymond James dropped their price target on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 18th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $169.19.
Johnson & Johnson Trading Down 2.3 %
NYSE JNJ opened at $145.60 on Monday. The company has a market cap of $378.41 billion, a price-to-earnings ratio of 10.81, a P/E/G ratio of 2.94 and a beta of 0.55. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $181.04. The business has a 50 day moving average price of $158.90 and a 200-day moving average price of $161.94. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 annualized dividend and a yield of 3.27%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 35.34%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Further Reading
- Five stocks we like better than Johnson & Johnson
- Energy and Oil Stocks Explained
- Is domestic travel back on track? Check out these companies
- How to Buy Gold Stock and Invest in Gold
- MarketBeat Week in Review – 10/23 – 10/27
- Industrial Products Stocks Investing
- Can casino stocks win big if economy slows?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
